Forte Biosciences Inc. reported a net loss of $17.7 million for the third quarter of 2025, compared to a net loss of $8.4 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $44.6 million, up from $28.3 million in the prior year period. Research and development expenses for the quarter were $15.1 million, up from $5.7 million a year earlier. General and administrative expenses were $3.2 million, compared to $2.8 million for the third quarter of 2024. As of September 30, 2025, Forte Biosciences had $93.4 million in cash and cash equivalents, with total assets at $97.1 million and stockholders' equity at $84.1 million. The company had approximately 12.5 million shares of common stock and 5.3 million prefunded warrants outstanding as of the end of the quarter.